BOE Technology vs Merck KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BOE Technology Group Co Ltd (000725.CS)

Q3 20262 Jul – 24 Sep 2026

▲4

BOE Rallies on Profit Surge, OLED Milestones, and Policy Support

Strong H1 earnings and OLED shipment growth First-half net profit jumped 61.6% to 5.2 billion yuan on revenue above 103.1 billion yuan. OLED shipments topped 80 million units, showing robust demand for BOE's display products.
Earnings and shipment growth are core fundamental drivers of the stock's rally.
China's first 8.6-gen OLED line enters mass production BOE started mass production on China's first 8.6-generation OLED line, a major technological milestone that boosts production efficiency and scale, strengthening its competitive position in the global display market.
This is a new operational milestone that enhances BOE's production capabilities and market leadership.
Institutional interest and Corning partnership progress Institutional visits surged to 238, focusing on glass substrate and optical interconnect tech. The Corning partnership advanced toward commercializing packaging substrates and foldable glass, signaling future growth avenues.
High institutional interest and partnership advancements indicate confidence and potential new revenue streams.
Shareholder buyback and favorable five-year plan The controlling shareholder plans to buy 500 million–1 billion yuan of stock, supporting the share price. China's 15th five-year plan named consumer electronics a priority, providing a policy tailwind for BOE.
Buyback and policy support directly boost investor confidence and demand outlook.

August 202628 Jul – 24 Sep 2026

▲4

BOE profit jumps, buybacks and state chip plan lift shares

Controlling shareholder to buy 500M–1B yuan of stock Beijing Electronics Holdings, BOE's controlling shareholder, plans to buy 500 million to 1 billion yuan of BOE A-shares. Big owners buying signals confidence and adds real demand for the stock, supporting the price.
New capital action by the controlling shareholder directly supports the share price.
First-half profit up 61.6% to 5.2 billion yuan BOE's first-half 2026 revenue topped 103.1 billion yuan and net profit rose 61.6% to 5.2 billion yuan. Stronger earnings show the display business is making more money, which supports a higher stock price.
The profit surge is the core fundamental driver of the stock's value.
OLED shipments top 80 million, 8.6-gen line starts mass production BOE shipped over 80 million OLED units in the first half, ranking first in China and second globally, and China's first 8.6-generation OLED line began mass production in June. This expands high-value output and future revenue.
New production capacity and shipment leadership drive future earnings growth.
China's five-year plan names consumer electronics a priority China's 15th five-year plan for electronics (2026–2030) names consumer electronics and basic electronics as priority industries, sending BOE shares up 2.1%. Expected state support improves the outlook for demand and investment in the sector.
New government policy directly benefits BOE's core business and investor sentiment.

Latest28 Jul – 24 Sep 2026

▲4

BOE profit jumps, buybacks and state chip plan lift shares

Controlling shareholder to buy 500M–1B yuan of stock Beijing Electronics Holdings, BOE's controlling shareholder, plans to buy 500 million to 1 billion yuan of BOE A-shares. Big owners buying signals confidence and adds real demand for the stock, supporting the price.
New capital action by the controlling shareholder directly supports the share price.
First-half profit up 61.6% to 5.2 billion yuan BOE's first-half 2026 revenue topped 103.1 billion yuan and net profit rose 61.6% to 5.2 billion yuan. Stronger earnings show the display business is making more money, which supports a higher stock price.
The profit surge is the core fundamental driver of the stock's value.
OLED shipments top 80 million, 8.6-gen line starts mass production BOE shipped over 80 million OLED units in the first half, ranking first in China and second globally, and China's first 8.6-generation OLED line began mass production in June. This expands high-value output and future revenue.
New production capacity and shipment leadership drive future earnings growth.
China's five-year plan names consumer electronics a priority China's 15th five-year plan for electronics (2026–2030) names consumer electronics and basic electronics as priority industries, sending BOE shares up 2.1%. Expected state support improves the outlook for demand and investment in the sector.
New government policy directly benefits BOE's core business and investor sentiment.

July 20262 Jul – 8 Jul 2026

▲3

BOE Surges on Glass Substrate Tech and Strong Profit Outlook

Institutional Buying and Glass Substrate Focus BOE attracted 238 institutional visits, the most of any stock, with focus on its glass substrate and optical interconnect technology. This signals strong professional investor confidence, pushing the stock price up as demand for AI-related components grows.
This is a new event that directly boosts investor sentiment and highlights BOE's technological edge.
Corning Partnership Advances BOE's collaboration with Corning has entered a substantive phase, targeting breakthroughs in glass-based packaging substrates, optical interconnects, perovskites, and foldable glass. This partnership could accelerate commercialization and open new revenue streams, driving the stock higher.
It reveals a concrete partnership that enhances BOE's growth prospects in advanced materials.
Strong First-Half Profit Forecast BOE expects first-half net profit of 5–5.5 billion yuan, up 54–69% year-on-year. This robust earnings growth confirms improving profitability and supports a higher stock price as investors anticipate continued strong performance.
It provides concrete financial guidance that directly impacts valuation and investor confidence.

2 Jul – 8 Jul 2026

▲3

BOE Surges on Glass Substrate Tech and Strong Profit Outlook

Institutional Buying and Glass Substrate Focus BOE attracted 238 institutional visits, the most of any stock, with focus on its glass substrate and optical interconnect technology. This signals strong professional investor confidence, pushing the stock price up as demand for AI-related components grows.
This is a new event that directly boosts investor sentiment and highlights BOE's technological edge.
Corning Partnership Advances BOE's collaboration with Corning has entered a substantive phase, targeting breakthroughs in glass-based packaging substrates, optical interconnects, perovskites, and foldable glass. This partnership could accelerate commercialization and open new revenue streams, driving the stock higher.
It reveals a concrete partnership that enhances BOE's growth prospects in advanced materials.
Strong First-Half Profit Forecast BOE expects first-half net profit of 5–5.5 billion yuan, up 54–69% year-on-year. This robust earnings growth confirms improving profitability and supports a higher stock price as investors anticipate continued strong performance.
It provides concrete financial guidance that directly impacts valuation and investor confidence.

Merck KGaA (MRK.XETRA)

Q3 202628 Jun – 29 Jul 2026

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.
This is the largest new deal and a direct driver of Merck KGaA's valuation.
UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.
Analyst positioning directly influences demand for the stock.
German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.
This is the main negative force on Merck KGaA's home-market profitability.
Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.
Pipeline and technology progress are core to Merck KGaA's long-term growth story.

July 202628 Jun – 29 Jul 2026

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.
This is the largest new deal and a direct driver of Merck KGaA's valuation.
UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.
Analyst positioning directly influences demand for the stock.
German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.
This is the main negative force on Merck KGaA's home-market profitability.
Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.
Pipeline and technology progress are core to Merck KGaA's long-term growth story.

Latest28 Jun – 29 Jul 2026

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.
This is the largest new deal and a direct driver of Merck KGaA's valuation.
UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.
Analyst positioning directly influences demand for the stock.
German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.
This is the main negative force on Merck KGaA's home-market profitability.
Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.
Pipeline and technology progress are core to Merck KGaA's long-term growth story.

Q2 202623 Jun – 26 Jun 2026

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.
This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.
Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.
This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.
Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.
A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

June 202623 Jun – 26 Jun 2026

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.
This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.
Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.
This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.
Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.
A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

23 Jun – 26 Jun 2026

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.
This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.
Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.
This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.
Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.
A new regulatory approval for a major drug adds to Merck's oncology revenue stream.